Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone408-973-7884
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$220,000.00
Profitability
Miscellaneous
Employees193
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.10. Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 44.32%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
3 analysts have issued twelve-month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $19.00 to $27.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 62.3% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.
What is the consensus analysts' recommendation for Cellular Biomedicine Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.
Has Cellular Biomedicine Group been receiving favorable news coverage?
Headlines about CBMG stock have been trending negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of -2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cellular Biomedicine Group.
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Vericel (VCEL), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY).
What other stocks do shareholders of Cellular Biomedicine Group own?
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
- Dr. Yihong Yao, Chief Scientific Officer (Age 51)
- Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
- Dr. Li Zhang, Chief Production Officer
- Derrick C. Li, Head of Strategy & Investor Relations
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $14.79.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $284.75 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.
What is Cellular Biomedicine Group's official website?
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
